MDMA (3,4-Methylenedioxymethamphetamine) or ecstasy: The neuropsychobiological implications of taking it at dances and raves

Neuropsychobiology

Volumn 50, Issue 4, 2004, Pages 329-335

  Parrott, A C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

3,4 Methylenedioxymethamphetamine; Amphetamine; Cognition; Ecstasy; Exercise; Heat; MDMA; Rave

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; NEUROTOXIN;

AROUSAL; DRUG RESPONSE; DRUG SELF ADMINISTRATION; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; HEAT; HUMAN; HYPERTHERMIA; LONG TERM EXPOSURE; NERVE ENDING; NEUROPSYCHOLOGY; NEUROTOXICITY; NOISE; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSYCHOBIOLOGY; REVIEW; SOCIAL INTERACTION; THERMOREGULATION;

ANIMALS; DANCING; DISEASE MODELS, ANIMAL; ENVIRONMENT; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGY; NEUROTOXICITY SYNDROMES; SEROTONIN; STREET DRUGS;

EID: 8344259984     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080961     Document Type: Review

References (61)

1. Pope HG, Ionescu-Pioggia M, Pope KW: Drug use and lifestyle among college undergraduates: A 30-year longitudinal study. Am J Psychiatry 2001;58:1519-1520.
2. Schifano F: Potential human neurotoxicity of MDMA ('ecstasy'): Subjective self-reports, evidence from an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000;42:25-33.
3. Parrott AC: Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: Cognitive and behavioural indices of change. Neuropsychobiology 2000;42:17-24.
4. Parrott AC: Human psychopharmacology of ecstasy (MDMA): A review of fifteen years of empirical research. Hum Psychopharmacol 2001;16:557-577.
5. van de Wijngaart GM, Braam R, de Bruin M, Fris M, Maalste NJM, Verbraeck HT: Ecstasy and the Dutch rave scene: A socio-epidemiological study. J Drug Issues 1999;19:697-702.
6. Winstock AR, Griffiths P, Stewart D: Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend 2001;64:9-17.
7. Tossman P, Boldt S, Tensil MD: The use of drugs within the techno party scene in European metropolitan cities. Addiction Res 2001;7:2-23.
8. DAWN: Club drugs. The Drug Abuse Warning Network (DAWN) report. Rockville, USA Department of Health and Human Services, December 2000.
9. Riley SCE, James C, Gregory D, Dingle H, Cadger M: Patterns of recreational drug use at dance events in Edinburgh, Scotland. Addiction 2001;96:1035-1047.
10. Suy K, Gijsenbergh F, Baute L: Emergency medical assistance during a mass gathering. Eur J Emerg Med 1999;6:249-254.
11. Colado MI, O'Shea E, Green AR: Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology 2004;173:249-263.
12. Green AR, Cross AJ, Goodwin GM: Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology 1995;119:247-260.
13. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI: The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 2003;55:463-508.
14. Hegadoren KM, Baker GB, Bourin M: 3,4-Methylenedioxy analogues of amphetamine: Defining the risks to humans. Neurosci Biobehav Rev 1998;23:539-553.
15. Ricaurte GA, Yuan J, McCann UD: (±)3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy')-induced serotonin neurotoxicity: Studies in animals. Neuropsychobiology 2000;42:5-10.
16. Dafters RI, Lynch E: Persistent loss of thermoregulation in the rat induced by 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') but not by fenfluramine. Psychopharmacology 1998;138:207-212.
17. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB: Effects of 3,4-methylenedioxymethamphetamine on thermoregulatory responses in the rat. Pharmacol Biochem Behav 1991;38:339-344.
18. Malberg JE, Seiden LS: Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998;18:5086-5094.
19. Green AR, Sanchez V, O'Shea E, Saadat KS, Elliott JM, Colado MI: Effect of ambient temperature and a prior neurotoxic dose of 3,4- methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 2004;173:264-269.
20. Mechan AO, O'Shea E, Elliott JM, Colado MI, Green AR: A neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) to rats results in a long term defect in thermoregulation. Psychopharmacology 2002;155:413-418.
21. Cornish JL, Schahnawaz Z, Thompson MR, Wong S, Morley KC, Hunt GE, McGregor IS: Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur J Pharmacol 2003;482:339-341.
22. Gunn J, Gurd M: The action of some amines related to adrenaline: Cyclohexylalkylamines. J Physiol 1940;97:453-470.
23. Dafters RI: Hyperthermia following MDMA administration in rats: Effects of ambient temperature, water consumption, and chronic dosing. Physiol Behav 1995;58:877-882.
24. Morton AJ, Hickey MA, Dean LC: Methamphetamine toxicity is potentiated by exposure to loud music. Neuroreport 2001;12:3277-3281.
25. Parrott A, Morinan A, Moss M, Scholey A: Understanding Drugs and Behaviour. Chichester, Wiley, 2004.
26. Walsh H: My first love - Clubbing, house music, and ecstasy. Observ Music Mag 2004;6:22-27.
27. Cohen RS: The Love Drug - Marching to the Beat of Ecstasy. New York, NY, Haworth Medical Press, 1998.
28. Parrott AC: Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 2002;71:837-844.
29. Davison D, Parrott AC: Ecstasy in recreational users: Self-reported psychological and physiological effects. Hum Psychopharmacol 1997;12:91-97.
30. Topp L, Hando J, Dillon P, Roche A, Solowij N: Ecstasy use in Australia: Patterns of use and associated harm. Drug Alcohol Depend 1999;55:105-115.
31. Tancer ME, Johanson CE, Freedman RR: MDMA elevates core temperature in warm and cold conditions in man (conference abstract). College on Problems of Drug Dependence Annual Conference, Bal Harbour, Fla., June 2003, p 169.
32. Liechti ME, Vollenweider FX: Which neuroreceptors mediate the subjective effects of MDMA in humans? Hum Psychopharmacol 2001;16:589-598.
33. Hermle L, Spitzer M, Borchardt D, Kovar KA, Gouzoulis E: Psychological effects of MDE in normal subjects. Neuropsychopharmacology 1993;8:171-176.
34. Henry JA, Jeffries KJ, Dawling S: Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992;340:384-387.
35. Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH: Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ('ecstasy') and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology 2003;166:202-211.
36. Ricaurte GA, Bryan G, Strauss L, Seiden LS, Schuster CR: Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985;229:986-988.
37. Schmidt CJ: Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J Pharmacol Exp Ther 1987;240:1-7.
38. Sprague JE, Everman SL, Nichols DE: An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 1988;19:427-441.
39. McGregor IS, Gurtman CG, Morley KC, Clemens KJ, Blockland A, Li KM, Cornish JL, Hunt GE: Increased anxiety and 'depressive' symptoms months after MDMA ('ecstasy') in rats: Drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology 2003;168:465-474.
40. Huether G, Zhou D, Ryuther E: Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4- methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners. J Neural Transm 1997;104:771-794.
41. 1H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA 'ecstasy') users. J Magn Reson Imag 1999;10:521-526.
42. McCann UD, Eligulashvili V, Ricaurte GA: (±)3,4- methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: Clinical studies. Neuropsychobiology 2000;42:11-16.
43. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron emission tomographic evidence of toxic effect of MDMA ('ecstasy') on brain serotonin neurones in human beings. Lancet 1998;352:1433-1437.
44. Reneman L, Booij J, Majoie CBL, van den Brink W, den Heeten GJ: Investigating the potential neurotoxicity of ecstasy (MDMA): An imaging approach. Hum Psychopharmacol 2001;16:579-588.
45. Reneman L, Majoie CBL, Flick H, den Heeten GJ: Reduced n-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxymethamphetamine (ecstasy) users: Preliminary results. Am J Neuroradiol 2002;23:231-237.
46. Morgan MJ: Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology 2000;152:230-248.
47. Parrott AC, Sisk E, Turner J: Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 2000;60:105-110.
48. Parrott AC, Milani R, Parmar R, Turner JJD: Ecstasy polydrug users and other recreational drug users in Britain and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology 2001;159:77-82.
49. Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J: Ecstasy-attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 2002;17:309-312.
50. Fox H, Parrott AC, Turner JJD: Ecstasy/MDMA related cognitive deficits: A function of dosage rather than awareness of problems. J Psychopharmacol 2001;15:273-281.
51. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ: Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ('ecstasy') polydrug users. Psychopharmacology 2002; 162:203-214.
52. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott A: Differential effects of ecstasy and cannabis on self reports of memory ability: A web-based study. Hum Psychopharmacol 2001;16:619-626.
53. Rodgers J, Buchanan T, Scholey AB, Heffernan TM, Ling J, Parrott AC: Patterns of drug use and the influence of gender on self reports of memory ability in ecstasy users: A web-based study. J Psychopharmacol 2003;17:379-386.
54. Verkes RJ, Gigsman HJ, Pieters MSM, Schoemaker RC, de Visser S, Kuijpers M: Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 2001;53:196-202.
55. Milani R, Turner JJD, Parrott AC, Parmar R: Recreational drug use and psychobiological problems, collaborative UK/Italy study: Ecstasy (MDMA) polydrug users findings. J Psychopharmacol 2000;14:A15.
56. Jacobsen LK, Mencl WE, Pugh KR, Skudlarski P, Krystal JH: Preliminary evidence of hippocampal dysfunction in adolescent MDMA ('ecstasy') users: Possible relationship to neurotoxic effects. Psychopharmacology 2004;173:383-390.
57. Hansen D, Maycock B, Lower T: 'Weddings, parties, anything ...', a qualitative analysis of ecstasy use in Perth, Western Australia. Int J Drug Policy 2001;12:181-199.
58. Parrott AC: Dancing hot on ecstasy: How drug and non-drug factors contribute to the neuropsychobiological deficits of recreational MDMA users. J Psychopharmacol, in press.
59. Boys A, Marsden J, Strang J: Understanding reasons for drug use amongst young people: A functional perspective. Health Educ Res 2001;16:457-469.
60. Chaperon F, Thiebot MH: Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999;13:243-281.
61. Parrott AC, Gouzoulis-Meyfrank E, Rodgers J, Solowij N: Ecstasy/MDMA and cannabis, the complexities of their interactive neuropsychobiological effects. J Psychopharmacol, in press.